1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Competitor Analysis: VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

  • February 2014
  • 70 pages
  • La Merie Publishing
Report ID: 2026764

Summary

Table of Contents

VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

The present Competitive Intelligence Report about VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) used to treat various cancers and ophthalmic diseases as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


The first generation of recombinant antibodies targeting VEGF consists of bevacizumab (Avastin) from Roche (Genentech) and ranibizumab (Lucentis) from Roche (Genentech) and Recently, VEGF-Trap Eye originating from Regeneron Pharmaceuticals has been approved for cancer and ophthalmic indications. Combined sales of all four VEGF targeting products were US$ 13,192 mln in 2013, of which 53.4% were from oncology sales.


The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground for development of second generation 'biobetter or biosuperior ' molecules as well as of biosimilar copies of the originator products.


The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:


- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

  • $ 4995
  • Industry report
  • April 2017
  • by GBI Research

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs Summary ...

Antibody Production Market By Type (Polyclonal Antibody, Monoclonal Antibody), By Process (Upstream Processing, Downstream Processing, Filtration), By End-Use, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • March 2017
  • by Grand View Research

The global antibody production market is expected to reach a value of USD 22.6 billion by 2025, according to a new report by Grand View Research, Inc. Increasing demand for therapeutic antibodies including ...

Biologics Market Analysis By Source (Microbial, Mammalian), By Products (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy), By Disease Category, By Manufacturing, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • March 2017
  • by Grand View Research

The global biologics market is anticipated to reach USD 399.5 billion by 2025, according to a new report by Grand View Research, Inc. Introduction of targeted therapies coupled with rising adoption of ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • June 2017
    114 pages
  • Therapy  

    Hormone  

    Musculoskeletal...  

  • United States  

View report >

Therapy Market and Monoclonal Antibody Market in the UK

  • June 2017
    39 pages
  • Therapy  

    Monoclonal Anti...  

  • United Kingdom  

View report >

Global Dermatological Condition Statistics and Therapy Market

  • June 2017
    138 pages
  • Dermatological ...  

    Therapy  

    Transplantation  

  • World  

    United States  

View report >

Related Market Segments :

Monoclonal Antibody
Targeted Therapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.